Chief Scientific Officer · Prelude Therapeutics Inc (PRLD)

Peggy Scherle

FY2025 is the first fiscal year CompBrief holds for Peggy Scherle as a named executive officer of Prelude Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$819,729

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A).

Peggy Scherle compensation by year

Prelude Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Prelude Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$473,416
Bonus$0
Stock awards$0
Option awards$145,523
Non-equity incentive$190,440
Pension and deferred compensation$0
All other$10,350
Total$819,729

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Prelude Therapeutics Inc DEF 14A filed April 29, 2026, accession 0001193125-26-191532, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option4,167—$10.58
Option39,375—$7.20
Option84,375—$4.59
Option175,000—$1.11

Per the Outstanding Equity Awards at Fiscal Year-End table in Prelude Therapeutics Inc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Prelude Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Krishna VaddiChief Executive Officer$1,348,000
Bryant LimChief Legal Officer, Corporate Secretary, and Chief Financial Officer$847,397
Peggy Scherle · this pageChief Scientific Officer$819,729

The full Prelude Therapeutics compensation record

free company brief

This page is one person within Prelude Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Prelude Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Prelude Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy